Literature DB >> 10203028

Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors.

S L Rowland-Jones1, T Dong, L Dorrell, G Ogg, P Hansasuta, P Krausa, J Kimani, S Sabally, K Ariyoshi, J Oyugi, K S MacDonald, J Bwayo, H Whittle, F A Plummer, A J McMichael.   

Abstract

HIV-specific cytotoxic T-lymphocytes (CTL) are believed to play a key part in the control of virus levels throughout HIV infection. An important goal of a potential prophylactic vaccine against HIV is therefore to elicit a strong CTL response which is broadly cross-reactive against a diverse range of HIV strains. We have detected HIV-specific CTL in two groups of highly-exposed but persistently seronegative female sex workers in Africa which show extensive cross-reactivity between different viral sequences. In a small group of women exposed to both HIV-1 and HIV-2 in Gambia, studied over 4 years, we have repeatedly detected HLA-B35-restricted CTL which exhibit cross-reactivity between the HIV-1 and HIV-2 sequences of the CTL epitopes. In women with particularly intense exposure to what are likely to be multiple clades of HIV-1 in Nairobi Kenya, we have detected CTL directed towards epitopes conserved between HIV-1 clades. In neither group is there any evidence that variation in CCR5 sequence or expression is responsible for their apparent resistance to HIV infection. However, in seropositive donors from Oxford infected with African strains of HIV-1, we have defined CTL responses which are specific for particular clades and have mapped some unique A clade CTL epitopes, together with others to highly-conserved regions of the virus. Further information about the extent of cross-reactive CTL immunity will be important for future vaccine design and evaluation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203028     DOI: 10.1016/s0165-2478(98)00179-5

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  23 in total

Review 1.  Proving HIV-1 immunity: new tools offer new opportunities.

Authors:  L J Picker
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death.

Authors:  S J Brodie; B K Patterson; D A Lewinsohn; K Diem; D Spach; P D Greenberg; S R Riddell; L Corey
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

3.  Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory.

Authors:  J P Christensen; P C Doherty; K C Branum; J M Riberdy
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene.

Authors:  Danilo R Casimiro; Aimin Tang; Ling Chen; Tong-Ming Fu; Robert K Evans; Mary-Ellen Davies; Daniel C Freed; William Hurni; Jose M Aste-Amezaga; Liming Guan; Romnie Long; Lingyi Huang; Virginia Harris; Denise K Nawrocki; Henryk Mach; Robert D Troutman; Lynne A Isopi; Krishna K Murthy; Karen Rice; Keith A Wilson; David B Volkin; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 5.  HLA and disease.

Authors:  Yogita Ghodke; Kalpana Joshi; Arvind Chopra; Bhushan Patwardhan
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

6.  Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.

Authors:  Emmanouil Papasavvas; Andrea Foulkes; Xiangfan Yin; Jocelin Joseph; Brian Ross; Livio Azzoni; Jay R Kostman; Karam Mounzer; Jane Shull; Luis J Montaner
Journal:  Immunology       Date:  2015-05-19       Impact factor: 7.397

7.  Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif.

Authors:  M A Altfeld; B Livingston; N Reshamwala; P T Nguyen; M M Addo; A Shea; M Newman; J Fikes; J Sidney; P Wentworth; R Chesnut; R L Eldridge; E S Rosenberg; G K Robbins; C Brander; P E Sax; S Boswell; T Flynn; S Buchbinder; P J Goulder; B D Walker; A Sette; S A Kalams
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

8.  Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1.

Authors:  Jianming Tang; Shenghui Tang; Elena Lobashevsky; Angela D Myracle; Ulgen Fideli; Grace Aldrovandi; Susan Allen; Rosemary Musonda; Richard A Kaslow
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Preinfection human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes failed to prevent HIV type 1 infection from strains genetically unrelated to viruses in long-term exposed partners.

Authors:  Yi Liu; Amanda Woodward; Haiying Zhu; Thomas Andrus; John McNevin; Jean Lee; James I Mullins; Lawrence Corey; M Juliana McElrath; Tuofu Zhu
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

10.  Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid.

Authors:  Jean D Boyer; Tara M Robinson; Michele A Kutzler; Gordon Vansant; David A Hokey; Sanjeev Kumar; Rose Parkinson; Ling Wu; Maninder K Sidhu; George N Pavlakis; Barbara K Felber; Charles Brown; Peter Silvera; Mark G Lewis; Joseph Monforte; Thomas A Waldmann; John Eldridge; David B Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.